Dong-Hwan Lee

List of Publications by Year
in descending order

30	337	932766	887659
papers	citations	10 h-index	17 g-index

31	31	31	521
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Rifampin Enhances the Glucose-Lowering Effect of Metformin and Increases OCT1 mRNA Levels in Healthy Participants. Clinical Pharmacology and Therapeutics, 2011, 89, 416-421.	2.3	75
2	Effect of HMGCR Variant Alleles on Lowâ€Density Lipoprotein Cholesterolâ€"Lowering Response to Atorvastatin in Healthy Korean Subjects. Journal of Clinical Pharmacology, 2012, 52, 339-346.	1.0	26
3	Development of a Pharmacokinetic Interaction Model for Co-administration of Simvastatin and Amlodipine. Drug Metabolism and Pharmacokinetics, 2014, 29, 120-128.	1.1	25
4	Pharmacokinetic Interaction Between Rosuvastatin and Telmisartan in Healthy Korean Male Volunteers: A Randomized, Open-label, Two-period, Crossover, Multiple-dose Study. Clinical Therapeutics, 2014, 36, 1147-1158.	1.1	25
5	A new population pharmacokinetic model for vancomycin in patients with variable renal function: Therapeutic drug monitoring based on extended covariate model using CKDâ€EPI estimation. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 750-759.	0.7	16
6	Pharmacokinetic Comparison of an Orally Disintegrating Film Formulation With a Film-Coated Tablet Formulation of Sildenafil in Healthy Korean Subjects: A Randomized, Open-Label, Single-Dose, 2-Period Crossover Study. Clinical Therapeutics, 2013, 35, 205-214.	1.1	14
7	Pharmacokinetic Interaction Between Rosuvastatin and Olmesartan: A Randomized, Open-label, 3-period, Multiple-dose Crossover Study in Healthy Korean Male Subjects. Clinical Therapeutics, 2014, 36, 1159-1170.	1.1	14
8	Pharmacokinetic Comparison of Sustained- and Immediate-Release Oral Formulations of Cilostazol in Healthy Korean Subjects: A Randomized, Open-Label, 3-Part, Sequential, 2-Period, Crossover, Single-Dose, Food-Effect, and Multiple-Dose Study. Clinical Therapeutics, 2011, 33, 2038-2053.	1.1	12
9	Pharmacokinetics of Rosuvastatin/Olmesartan Fixed-Dose Combination: A Single-Dose, Randomized, Open-Label, 2-Period Crossover Study in Healthy Korean Subjects. Clinical Therapeutics, 2013, 35, 915-922.	1.1	12
10	Pharmacokinetic Interaction Between Rosuvastatin and Metformin in Healthy Korean Male Volunteers: A Randomized, Open-label, 3-period, Crossover, Multiple-dose Study. Clinical Therapeutics, 2014, 36, 1171-1181.	1.1	11
11	Prospective Cohort Study of Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Adults on Extracorporeal Membrane Oxygenation. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	10
12	Pharmacokinetic Comparison of 2 Fixed-Dose Combination Tablets of Amlodipine and Valsartan in Healthy Male Korean Volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, Crossover Study. Clinical Therapeutics, 2013, 35, 934-940.	1.1	9
13	Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	9
14	Population Pharmacokinetic Analysis of Meropenem After Intravenous Infusion in Korean Patients With Acute Infections. Clinical Therapeutics, 2018, 40, 1384-1395.	1.1	9
15	Population Pharmacokineticâ€"Pharmacodynamic Analysis to Compare the Effect of Moxifloxacin on QT Interval Prolongation Between Healthy Korean and Japanese Subjects. Clinical Therapeutics, 2016, 38, 2610-2621.	1.1	8
16	Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation. Frontiers in Pharmacology, 2021, 12, 768912.	1.6	8
17	Parameter estimation for sigmoid E_{max} models in exposure-response relationship. Translational and Clinical Pharmacology, 2017, 25, 74.	0.3	7
18	10-Phenyltriazoyl Artemisinin is a Novel P-glycoprotein Inhibitor that Suppresses the Overexpression and Function of P-glycoprotein. Current Pharmaceutical Design, 2019, 24, 5590-5597.	0.9	7

#	Article	IF	Citations
19	The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation. Acute and Critical Care, 2022, 37, 177-184.	0.6	7
20	Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation. Journal of Antimicrobial Chemotherapy, 2022, 77, 1353-1364.	1.3	6
21	Population Pharmacokinetic Analysis of Diurnal and Seasonal Variations of Plasma Concentrations of Cilostazol in Healthy Volunteers. Therapeutic Drug Monitoring, 2014, 36, 771-780.	1.0	5
22	Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation. Pharmaceutics, 2021, 13, 1861.	2.0	5
23	Nephrotoxicity of amikacin in noncritically ill patients. Clinical Nephrology, 2019, 92, 201-207.	0.4	4
24	Effect of pharmacokinetic model misspecification on antibiotic probability of target attainment predicted by Monte Carlo simulation. International Journal of Clinical Pharmacology and Therapeutics, 2019, 57, 362-374.	0.3	4
25	Predicting Antibiotic Effect of Vancomycin Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation: Dense Sampling versus Sparse Sampling. Antibiotics, 2022, 11, 743.	1.5	4
26	Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function. Therapeutic Drug Monitoring, 2018, 40, 425-434.	1.0	3
27	Impact of Sampling Period on Population Pharmacokinetic Analysis of Antibiotics: Why do You Take Blood Samples Following the Fourth Dose?. Pharmaceuticals, 2020, 13, 249.	1.7	1
28	The Safety and the Pharmacokinetics and Pharmacodynamics of a Pegylated Interferon Alpha-2a Formulation, Dong-A's DA-3021. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2010, 18, 117.	0.1	1
29	Assessment of statistical power for covariate effects in data from phase I clinical trials. Translational and Clinical Pharmacology, 2015, 23, 31.	0.3	0
30	1540. A Population Pharmacokinetic Model for Vancomycin in Korean Patients Receiving Extracorporeal Membrane Oxygenation Therapy: A Prospective Study. Open Forum Infectious Diseases, 2019, 6, S562-S562.	0.4	0